QuidelOrtho Corporation $QDEL Shares Bought by Newtyn Management LLC

Newtyn Management LLC lifted its stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 45.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,625,000 shares of the company’s stock after acquiring an additional 2,066,528 shares during the quarter. QuidelOrtho makes up 14.7% of Newtyn Management LLC’s holdings, making the stock its biggest holding. Newtyn Management LLC owned about 9.66% of QuidelOrtho worth $116,037,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. increased its position in QuidelOrtho by 7.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock valued at $337,925,000 after purchasing an additional 819,908 shares during the period. BlackRock Inc. acquired a new position in shares of QuidelOrtho in the 2nd quarter worth approximately $196,212,000. Invesco Ltd. boosted its stake in shares of QuidelOrtho by 19.4% in the 4th quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock valued at $99,122,000 after purchasing an additional 563,893 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of QuidelOrtho by 7.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,048,768 shares of the company’s stock valued at $50,085,000 after purchasing an additional 212,481 shares during the last quarter. Finally, State Street Corp increased its position in shares of QuidelOrtho by 1.3% during the fourth quarter. State Street Corp now owns 2,704,355 shares of the company’s stock worth $77,236,000 after buying an additional 35,616 shares during the period. 99.00% of the stock is owned by institutional investors and hedge funds.

QuidelOrtho Stock Performance

Shares of QuidelOrtho stock opened at $14.74 on Monday. The business has a 50-day simple moving average of $15.93 and a 200 day simple moving average of $15.94. QuidelOrtho Corporation has a one year low of $9.92 and a one year high of $35.58. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -0.96 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.18. The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 earnings per share. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, research analysts anticipate that QuidelOrtho Corporation will post 0.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QDEL has been the subject of a number of analyst reports. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Citigroup increased their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 12th. Finally, UBS Group reissued a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Three analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, QuidelOrtho currently has an average rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.